European Commission 9 August 2010, Commission Decision of 09/08/2010 declaring a concentration to be compatible with the common market (Case No COMP/M.5778 - NOVARTIS / ALCON) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

Also known as

The European Commission declared the acquisition of Alcon Inc. by Novartis AG compatible with the internal market under Council Regulation (EC) No 139/2004, subject to structural and behavioral commitments. The Commission identified serious doubts regarding horizontal overlaps in several ophthalmic pharmaceutical and consumer vision markets, including anti-infectives, anti-glaucoma products, and lens care preparations. To resolve these concerns, Novartis committed to the divestiture of specific business units, the transfer of distribution rights, and the deregistration of certain products across the European Economic Area.AI